CA1176984A - Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux - Google Patents

Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux

Info

Publication number: CA1176984A
Authority: CA; Canada
Prior art keywords: treatment; ulcers; animals; gastric; gastritis
Prior art date: 1981-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000387085A

Other languages

English (en)

Inventor

Eraldo Borgo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Made Italiana SRL

Original Assignee

Made Italiana SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-10-01

Filing date

1981-10-01

Publication date

1984-10-30

1981-10-01 Application filed by Made Italiana SRL filed Critical Made Italiana SRL

1981-10-01 Priority to CA000387085A priority Critical patent/CA1176984A/fr

1984-10-30 Application granted granted Critical

1984-10-30 Publication of CA1176984A publication Critical patent/CA1176984A/fr

Status Expired legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
230000002496 gastric effect Effects 0.000 title abstract description 19
208000007882 Gastritis Diseases 0.000 title abstract description 13
206010020601 Hyperchlorhydria Diseases 0.000 title abstract description 5
208000008469 Peptic Ulcer Diseases 0.000 title abstract description 5
231100000029 gastro-duodenal ulcer Toxicity 0.000 title abstract description 5
239000000203 mixture Substances 0.000 claims abstract description 17
235000010443 alginic acid Nutrition 0.000 claims abstract description 12
229960001126 alginic acid Drugs 0.000 claims abstract description 12
229920000615 alginic acid Polymers 0.000 claims abstract description 12
239000000783 alginic acid Substances 0.000 claims abstract description 12
150000004781 alginic acids Chemical class 0.000 claims abstract description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
239000004480 active ingredient Substances 0.000 claims abstract description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 4
239000000843 powder Substances 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 15
241001465754 Metazoa Species 0.000 description 35
208000025865 Ulcer Diseases 0.000 description 26
231100000397 ulcer Toxicity 0.000 description 26
241000700159 Rattus Species 0.000 description 12
238000012360 testing method Methods 0.000 description 10
210000002784 stomach Anatomy 0.000 description 9
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 8
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
210000004877 mucosa Anatomy 0.000 description 7
230000001575 pathological effect Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
208000007107 Stomach Ulcer Diseases 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
206010048714 Gastroduodenitis Diseases 0.000 description 4
KXEMQEGRZWUKJS-UHFFFAOYSA-N Raufloridine Natural products COC1=CC=C2C(CCN3CC4C(C)OC=C(C4CC33)C(=O)OC)=C3NC2=C1 KXEMQEGRZWUKJS-UHFFFAOYSA-N 0.000 description 4
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
230000007059 acute toxicity Effects 0.000 description 4
231100000403 acute toxicity Toxicity 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
210000004051 gastric juice Anatomy 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 4
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
208000037157 Azotemia Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010070863 Toxicity to various agents Diseases 0.000 description 3
230000001458 anti-acid effect Effects 0.000 description 3
208000000718 duodenal ulcer Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
201000005917 gastric ulcer Diseases 0.000 description 3
208000036796 hyperbilirubinemia Diseases 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
244000309715 mini pig Species 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
206010018901 Haemoglobinaemia Diseases 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
229920000715 Mucilage Polymers 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000001785 acacia senegal l. willd gum Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
230000007665 chronic toxicity Effects 0.000 description 2
231100000160 chronic toxicity Toxicity 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229960000443 hydrochloric acid Drugs 0.000 description 2
235000011167 hydrochloric acid Nutrition 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100504379 Mus musculus Gfral gene Proteins 0.000 description 1
101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
-1 compresses Substances 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
230000002178 gastroprotective effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
150000002892 organic cations Chemical class 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
208000024981 pyrosis Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000013049 sediment Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000009154 spontaneous behavior Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
230000001562 ulcerogenic effect Effects 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000387085A 1981-10-01 1981-10-01 Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux Expired CA1176984A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000387085A CA1176984A (fr)	1981-10-01	1981-10-01	Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000387085A CA1176984A (fr)	1981-10-01	1981-10-01	Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux

Publications (1)

Publication Number	Publication Date
CA1176984A true CA1176984A (fr)	1984-10-30

Family

ID=4121068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000387085A Expired CA1176984A (fr)	1981-10-01	1981-10-01	Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux

Country Status (1)

Country	Link
CA (1)	CA1176984A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010108494A1 (fr) *	2009-03-25	2010-09-30	S-Biotek Holding Aps	Traitement de dyspepsie par alginate

1981
- 1981-10-01 CA CA000387085A patent/CA1176984A/fr not_active Expired

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010108494A1 (fr) *	2009-03-25	2010-09-30	S-Biotek Holding Aps	Traitement de dyspepsie par alginate

Legal Events

Date	Code	Title	Description
2001-10-30	MKEX	Expiry

Publication	Publication Date	Title
Robertson et al.	1981	Factors influencing the crystallisation of calcium oxalate in urine-critique
Coe et al.	1980	Uric acid saturation in calcium nephrolithiasis
Williams et al.	1977	Nephrolithiasis
US4965065A (en)	1990-10-23	Gastroprotective process and compositions
Gault et al.	1991	Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones
Goldwasser et al.	1986	Calcium stone disease: an overview
King Jr	1971	Currents in renal stone research
Krall et al.	1957	Early clinical evaluation of a new oral non-sulfonylurea hypoglycemic agent.
Oren et al.	1984	Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis
Rosenow et al.	1923	The production of urinary calculi by the devitalization and infection of teeth in dogs with streptococci from cases of nephrolithiasis
Baggio et al.	1983	Juvenile renal stone disease: a study of urinary promoting and inhibiting factors
Ogawa et al.	1993	Accumulation of 1-methyl-tetrahydro-Β-carboline-3-carboxylic acid in blood and organs of rat. A possible causative substance of eosinophilia-myalgia syndrome associated with ingestion ofl-tryptophan
CA1176984A (fr)	1984-10-30	Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux
Grove et al.	1950	Experimental urolithiasis. II. The influence of urine volume upon calculi experimentally produced upon foreign bodies
Lundell	1974	Histamine metabolism of the gastric mucosa following antrectomy
DE60121771T2 (de)	2007-08-09	Verwendung von alginaten zur hemmung des pepsins
GB2107184A (en)	1983-04-27	Gastric compositions containing alginic acid
O'brien et al.	1967	Urinary pyrophosphate in normal subjects and in stone formers
Marks et al.	1985	Maintenance therapy with sucralfate reduces rate of gastric ulcer recurrence
Sidell et al.	1971	Toxogonin: Oral administration to man
Light et al.	1973	Urinary ionized calcium in urolithiasis Effect of cranberry juice
Boass et al.	1963	An assay for gastric intrinsic factor
Paul et al.	1966	Studies on the Inhibition of Intestinal Absorption of Radioactive Strontium: V. The Effect of Administration of Calcium Alginate
FOGELSON	1935	Gastric Mucin Treatment for Peptic Ulcer: A Report Based on Questionnaires
Burr	1981	Calculosis in paraplegia

CA1176984A - Composes pharmaceutiques pour le traitement de l'hyperacidite gastrique, de la gastrite et des ulceres gastroduodenaux - Google Patents

Info

Links

Landscapes

Priority Applications (1)

Applications Claiming Priority (1)

Publications (1)

Family

ID=4121068

Family Applications (1)

Country Status (1)

Cited By (1)

Cited By (1)

Similar Documents

Legal Events